(NASDAQ: LBRX) Lb Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.91%.
Lb Pharmaceuticals's earnings in 2026 is N/A.On average, 11 Wall Street analysts forecast LBRX's earnings for 2026 to be -$100,686,593, with the lowest LBRX earnings forecast at -$104,543,603, and the highest LBRX earnings forecast at -$94,848,026. On average, 11 Wall Street analysts forecast LBRX's earnings for 2027 to be -$124,410,787, with the lowest LBRX earnings forecast at -$148,946,530, and the highest LBRX earnings forecast at -$107,795,535.
In 2028, LBRX is forecast to generate -$114,221,973 in earnings, with the lowest earnings forecast at -$146,417,250 and the highest earnings forecast at -$90,331,454.